BQCA |
رقم الكتالوجGC15758
One-Click Copy Product Info
|
BQCA هو مُعدِّل خيفي انتقائي للغاية لـ M1 mAChR
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 338747-41-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Benzyl Quinolone Carboxylic Acid (BQCA) is a highly selective allosteric potentiator of the M1 muscarinic acetylcholine receptor (mAChR) [1].
M1 is most abundantly mAChR expressed in the hippocampus, cortex, and striatum, and localizes to postsynaptic membranes. M1 regulates several ion channels such as KCNQ inwardly rectifying K+currents, voltage-gated calcium channels, and NMDA receptors. M1 mediates the cognitive effects of ACh. M1 activation could slow AD progression by reducing Aβ42 peptides [1].
In vitro: BQCA alone showed no effect on calcium mobilization up to 10 μM but increased ACh potency 128.8 ± 20.1-fold at 100 μM. In CHO cells stably expressing human M1, BQCA (100 μM) activated M1 in the absence of ACh to an approximate 50% maximal response. BQCA had no effect on M2–M5, indicating 100-fold selectivity [1]. BQCA dose-dependently reduced the concentration of acetylcholine required to activate the M1 receptor [1]. The effective range for potentiation of M1 in cells by BQCA was 0.1 to 100 μM, with an inflection point value of 845 nM when 3 nM acetylcholine was used [1].
In vivo: In wild-type mice, BQCA (15 mg/kg) induced c-fos and arc RNA in the cortex, hippocampus, and cerebellum and the arc was also elevated in the striatum. BQCA had no effect in M1-/- mice. In wild-type mice, oral administration of 15 mg/kg BQCA increased the ratio of phosphoERK (pERK) to total ERK by 28%. BQCA showed excellent brain penetration and increased the firing rate of medial prefrontal cortex neurons in vivo in rats [2].
References:
[1] Ma L, Seager M A, Wittmann M, et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation[J]. Proceedings of the National Academy of Sciences, 2009, 106(37): 15950-15955.
[2] Shirey J K, Brady A E, Jones P J, et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning[J]. Journal of Neuroscience, 2009, 29(45): 14271-14286.
Kinase experiment: | Competition binding reactions used 25 μg human M1 CHO membrane protein, BQCA or vehicle, and 0.15 nM [3H]NMS in 96-well deep-well plates. Binding reactions (30 °C for 2-3 h) are terminated by rapid filtration. Nonspecific binding is determined by adding 10 μM atropine. Filter plates are ished 4×with ice-cold 20 mM HEPES, 100 mM NaCl, and 5 mM MgCl2, pH 7.4 using a 96-well harvester. Plates are dried and radioactivity counted with a microplate scintillation counter[1]. |
Animal experiment: | Rats: Male Sprague-Dawley rats weighing 225-250 g, are injected i.p. with the micro-suspension (containing 10% tween 80) of BQCA at the dose of 10 mg/kg. The blood and whole brain tissue samples are collected at 0.5, 1, 2, 4 and 8 h. Blood samples are collected through cardiac puncture in EDTA vacutainer tubes. The plasma is separated by centrifugation and stored at −80°C until analysis. The animals are decapitated and the whole brain tissue are removed and immediately frozen on dry ice[2]. Mice: Mice are dosed I.P. with BQCA in 5% beta-cyclodextrin and/or 0.3 mg/kg scopolamine in 0.9% saline 30 min before placement into a chamber for 2 min before 2 tone-footshock pairings (3 kHz, 85 dB tone for 30 s co-terminated with a 0.5 mA, 1 s shock) 2 min apart. Mice are removed to their home cage 30 s after the last pairing. Twenty-four hours later mice are placed into the same chamber and freezing is measured by Video Freeze[1]. |
References: [1]. Ma L, et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15950-5. | |
| Cas No. | 338747-41-4 | SDF | |
| Chemical Name | 1,4-dihydro-1-[(4-methoxyphenyl)methyl]-4-oxo-3-quinolinecarboxylic acid | ||
| Canonical SMILES | COC1=CC=C(CN2C(C=CC=C3)=C3C(C(C(O)=O)=C2)=O)C=C1 | ||
| Formula | C18H15NO4 | M.Wt | 309.3 |
| الذوبان | ≥ 30.9mg/mL in DMSO with gentle warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2331 mL | 16.1655 mL | 32.3311 mL |
| 5 mM | 646.6 μL | 3.2331 mL | 6.4662 mL |
| 10 mM | 323.3 μL | 1.6166 mL | 3.2331 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)